UBS reiterates its buy rating on the stock, but lowers its price target to E178 (from E186), which still represents 18% upside potential.

'We are revising our target rating after the failure of xevinapant in head and neck cancer. We continue to value bioprocesses and semiconductor recovery engines in the second half and into 2025' says UBS.

Merck has announced the discontinuation of a phase III clinical trial evaluating an experimental treatment for head and neck cancer. The German group explains that it took its decision following an opinion from the study's independent monitoring committee, which considered that the trial was unlikely to achieve its primary objective, namely to improve patient survival.

Merck KGaA has confirmed its qualitative forecasts for 2024, with a return to organic growth. It expects revenues of €20.6 to €22.1 billion, adjusted EBITDA of €5.7 to €6.3 billion, and adjusted EPS of €8.05 to €9.10.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.